Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
January 16, 2016 12:00 AM

War on cancer, take two

Maria Castellucci
Sabriya Rice
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Getty Images
    Dr. Christian Hinrichs, assistant clinical investigator at the Center for Cancer Research at the National Cancer Institute, helped develop advanced, cutting-edge procedures to cure two women of a rare form of cervical cancer.

    With the signing of the National Cancer Act and the requested appropriation of $100 million for research, President Richard Nixon launched the first “war on cancer” in 1971. It was a campaign “to find a cure.” To give hope to cancer patients, Nixon asserted during a televised address that everything possible “will now be done.”

    The past 40 years have brought a greater understanding of the disease's genomics and the related mortality rate has dropped by 23% since 1991, translating to more than 1.7 million deaths averted through 2012. Yet optimism about finding cures has tempered, dampened by high drug costs, lack of collaboration and unfulfilled promises.

    “Let's make America the country that cures cancer once and for all,” said President Barack Obama, receiving a round of applause during his final State of the Union address. Obama tasked Vice President Joe Biden with spearheading a new “moonshot” approach to fighting cancer. Biden said he would break down silos that prevent data-sharing and ultimately, “make a decade worth of advances in five years.”

    Last week, some of that work began. The National Cancer Institute said it would launch a database this summer that contains information about genetic mutations and cancer treatments. Data will come from as many as 50,000 patients and clinical-trial participants in the Therapeutically Applicable Research to Generate Effective Treatments program, as well as the Cancer Genome Atlas.

    “There's never going to be (just) one cure,” said Dr. Julie Vose, president of the American Society of Clinical Oncology. Cancer is thousands of different diseases. Presentations and treatment can vary from patient to patient. Vose warned that it's “impossible to generalize treatments to all patients with cancer.”

    To that end, ASCO issued a timely policy statement last week noting how the personalized nature of cancer treatment has resulted in a flood of clinical pathways—protocols that guide which treatment should be chosen for a patient's specific diagnosis. The administrative burden of managing those pathways “is at a breaking point,” experts say.

    Also at a breaking point are the overwhelming costs of conducting clinical research, comparing existing therapies and the steep prices that preclude some patients from affording life-saving treatment.

    The number of Americans taking at least $100,000 worth of prescription drugs annually from 2013 to 2014 tripled, according to Express Scripts. High-cost cancer medications were partly to blame.

    MH Takeaways

    The oncology community agrees that any coordinated approach could address the challenges currently facing clinical research.

    The most promising recent advancements—such as immunotherapy, which uses the body's natural defenses to fight cancer—could cost as much as $130,000 for a 12-week course of treatment. Oncologist Dr. Peter Eisenberg at Marin General Hospital in Greenbrae, Calif., said he is fed up with prescribing “fabulously expensive and marginally effective” drugs.

    And profiteering from drugs is a trend that “shows no sign of slowing,” added Dr. Lee Newcomer, senior vice president of oncology, genetics and women's health at UnitedHealthcare. To help control costs, the insurer—the largest in the country—in 2009 launched a collaboration with five oncology groups. They use a value-based payment model based on best practices and patient outcomes.

    The national focus on quality and value has also bolstered interest in comparative effectiveness studies that assess the merits of new drugs. But even that research faces challenges.

    A 2014 NCI analysis found that some cancer drugs are so expensive they hinder post-market trials that compare which ones work best. It's not in the best interests of the manufacturer of a more expensive drug to provide free medication for those trials, making it necessary for a third party to finance the research. A study comparing the brand and generic versions of two prostate cancer drugs could rack up to $70 million in drug costs alone, the authors wrote. Oncologists have urged changes in federal law to allow Medicare to negotiate drug prices.

    Dr. Vincent DeVita, former director of the NCI and a pioneer in oncology research, argues that the U.S. Food and Drug Administration could help by speeding up the approval process, which now can take more than two years. “The ability to innovate is gone,” DeVita said. “The FDA has become the oncologist.”

    Related Content

    Clinical pathways for cancer face fork in the road

    Also, the nation's investment in cancer research has been dropping since 2003, partly because the NCI has lost nearly 25% of its budget, the agency said. Its budget was increased by $260 million in the recent 2016 budget, but the agency had requested more. Additional funding could help cover expenses for transportation and lost work time, issues that often prevent participation in clinical trials.

    Less than 5% of adult patients participate in studies, according to ASCO. And as physicians see more patients in the changing healthcare climate, they may be too busy to discuss the option.

    Most patients don't even know to ask about studies, said Dr. Michael Seiden, chief medical officer of the US Oncology Network and McKesson Specialty Health.

    In light of the challenges seen over the past 40-plus years, experts say any new approach to curing cancer, moonshot or otherwise, must get back to the basics.

    Historically, clinical breakthroughs, including drugs and other therapies, have been the shiny new thing. Most recently, the pending 21st Century Cures Act aims to fast-track the most promising treatments. But the “gee whiz stuff” isn't all there is to it, said Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society.

    Efforts to reduce obesity and smoking and boost access to primary and preventive care could significantly cut the cancer mortality rate. “We could do much better in coordinating our efforts in that regard,” Lichtenfeld said.

    Eisenberg added that specialty cancer drugs have diverted attention from research into the chromosomal abnormalities that result in cancer variations among patients. “Basic research is not very sexy,” he said. But “if we better understood the science, we could better design the drugs.”

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    abortion-pill-misoprostol-legal
    Abortion pill case advances to appeals court, on course to Supreme Court
    young doctor medical resident
    Federal physician recruitment program at risk
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing